Oriental Aromatics: consol PBT more than doubles YoY to ₹5.27 Cr; subsidiary losses cap PAT

Oriental Aromatics' consolidated revenue rose 15.2% YoY to ₹259.81 Cr (Q1 FY26: ₹225.52 Cr) but fell 8.0% QoQ from Q4 FY26's ₹282.37 Cr. Consolidated PBT of ₹5.27 Cr more than doubled YoY (+105.7% from ₹2.56 Cr) on the back of that topline growth, though it was down 28.1% sequentially from ₹7.33 Cr. Consolidated PAT of ₹2.51 Cr looks dramatic YoY (+398.9% from a thin ₹0.50 Cr base) but that headline overstates the improvement: the year-ago quarter carried an unusually high 80.3% effective tax rate (tax of ₹2.06 Cr on PBT of just ₹2.56 Cr), versus 52.3% this quarter (₹2.76 Cr tax on ₹5.27 Cr PBT). PBT growth is the cleaner read of the underlying business, and even that is flattered by a still-elevated tax rate rather than a return to normalcy — there is no disclosed one-off tax item, so this reads as ongoing tax inefficiency rather than a discrete exceptional item. Consolidated NPM improved to 0.97% from 0.22% YoY but slipped from 1.39% in Q4 FY26; the underlying operating margin (PBT plus finance costs and depreciation, over revenue) was roughly flat at ~8.0% versus ~8.1% a year ago, indicating the raw-material and cost pressures management flagged for FY26 have not meaningfully reversed yet.

On basis: standalone PAT of ₹8.15 Cr (EPS ₹2.42) is more than 3x the consolidated PAT of ₹2.51 Cr (EPS ₹0.75) — investors reading only the standalone number would see a materially rosier picture. The gap is entirely a subsidiary story: Oriental Aromatics & Sons and the Indonesian unit PT Oriental Aromatics together dragged consolidated PBT down by roughly ₹5.64 Cr versus standalone, consistent with a persistent (not new) drag over the last three quarters. There is no formal analyst consensus available for this small-cap (~₹1,073 Cr market cap per recent quotes) to benchmark against, so vsStreet is unknown; management's own FY27 guidance from the Q4 FY26 call — progressive margin benefit from internal cost/process improvements, and the Mahad facility targeting ₹50-65 Cr revenue at optimal utilization with EBITDA neutrality aspired within a year at 75-80% utilization — cannot be verified against this filing since the company reports only one segment ('Fine Chemicals') with no Mahad-specific breakout; that verdict will have to come from the July 31 earnings call. The quarter's only other corporate action was the appointment of Nitin Budhavalekar as VP–Sales Fragrance effective August 1, 2026, which is organizational and not a driver of this quarter's numbers. A ₹0.50/share dividend recommended in May 2026 relates to the FY26 results, not this quarter.

The stock went into the print at ₹380.85, up 21.3% over the past month of trading.

For context: this is the second-highest quarterly PAT of the last 6 quarters.